Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications - BioSpace

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications  BioSpace

Comments

Popular posts from this blog

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze - Business Pulze

Healthcare layoff tracker—Walmart cuts 74 virtual health jobs - Fierce healthcare